You are here

  • Home
  • Archive
  • Volume 21, Issue 5
  • Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Article info

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta analysis
Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Authors

  1. Correspondence to: Department of Nephrology, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia; david.johnson2{at}health.qld.gov.au
View Full Text

Citation

Johnson DW
Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes
BMJ Evidence-Based Medicine 2016;21:178.

Publication history

  • First published August 12, 2016.
Online issue publication 
September 23, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/